Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kuppermann

Showing results (71-80 of 250) with videos related to

Pageof 25
Sort By:
American Journal of Ophthalmology|October 18, 2005
Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhageBaruch D Kuppermann, Edgar L Thomas, Marc D de Smet, et al.
Journal of Vitreoretinal Diseases|August 18, 2025
Secondary Macular Hole Closure With Sub-Tenon Triamcinolone AcetonideReza Azimi, Amr K Hassan, Elina Ghafari, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 20, 2018
Effects of Brimonidine on Retinal Pigment Epithelial Cells and Müller Cells Exposed to Amyloid-Beta 1-42 Peptide In VitroSean W Tsao, Rami Gabriel, Kunal Thaker, et al.
Eye (London, England)|October 17, 2022
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Ocular Immunology and Inflammation|July 9, 2021
Faricimab: Two in the Bush Is Proving Better than One in the Hand?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|March 29, 2024
Global experience of faricimab in clinical settings - a reviewAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Pharmacotherapy|July 14, 2015
Advances in pharmacotherapy for wet age-related macular degenerationMartina Santarelli, Laura Diplotti, Francesco Samassa, et al.
Eye (London, England)|June 23, 2021
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|January 20, 2022
On label bevacizumab for retina: where it standsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|July 20, 2023
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Pageof 25

Showing results (71-80 of 250) with videos related to

Sort By:
Pageof 25
American Journal of Ophthalmology|October 18, 2005
Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhageBaruch D Kuppermann, Edgar L Thomas, Marc D de Smet, et al.
Journal of Vitreoretinal Diseases|August 18, 2025
Secondary Macular Hole Closure With Sub-Tenon Triamcinolone AcetonideReza Azimi, Amr K Hassan, Elina Ghafari, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|October 20, 2018
Effects of Brimonidine on Retinal Pigment Epithelial Cells and Müller Cells Exposed to Amyloid-Beta 1-42 Peptide In VitroSean W Tsao, Rami Gabriel, Kunal Thaker, et al.
Eye (London, England)|October 17, 2022
Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Ocular Immunology and Inflammation|July 9, 2021
Faricimab: Two in the Bush Is Proving Better than One in the Hand?Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|March 29, 2024
Global experience of faricimab in clinical settings - a reviewAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Pharmacotherapy|July 14, 2015
Advances in pharmacotherapy for wet age-related macular degenerationMartina Santarelli, Laura Diplotti, Francesco Samassa, et al.
Eye (London, England)|June 23, 2021
Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|January 20, 2022
On label bevacizumab for retina: where it standsAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|July 20, 2023
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Pageof 25